RPG pays up to ₹135 crore, 7x sales, for an approved API plant
Raghava Life Sciences’ API business did about ₹19 crore in FY26. What RPG is buying is the approval: WHO GMP and EU GMP, ~300 kl of capacity and 29 molecules.
RPG pays up to ₹135 crore, 7x sales, for an approved API plant
Raghava Life Sciences’ API business did about ₹19 crore in FY26. What RPG is buying is the approval: WHO GMP and EU GMP, ~300 kl of capacity and 29 molecules.
₹ CRORE
7.1x FY26 sales, for a plant near Hyderabad
The plant’s ₹200 crore potential is a management estimate reported in the press, not a filed figure. ₹135 crore is a ceiling, subject to adjustments.
RPG Life Sciences, BSE filing of 29 July 2026 · FY26
Share it
The numbers
Embed it on your site
The code carries a credit line that links back to this page. Keep it with the chart.